FDA Approves Biocon Biologics’ Biosimilar YESINTEK: What You Need to Know
The U.S. Food and Drug Administration (FDA) has approved Biocon Biologics’ YESINTEK™ (ustekinumab-kfce), a biosimilar to Stelara® (ustekinumab). YESINTEK™ is authorized for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. ✏️▫️Clinical trials have demonstrated that YESINTEK™ is equivalent to Stelara® in terms of efficacy, safety, immunogenicity, and pharmacokinetics. A phase 3 randomized, double-blind, … Read more